Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options.

ABSTRACT: Overall, around 40% of patients with diffuse large B-cell lymphoma (DLBCL) have refractory disease or relapse after the first line of treatment. Until relatively recently, the prognosis of patients with relapsed or refractory DLBCL was very poor and treatment options were very limited. In recent years, several novel therapies have been approved that provide more effective options than conventional chemotherapy and that have manageable toxicity profiles. CAR-T cell therapy has become the new standard treatment for patients with refractory or early relapsed DLBCL, based on the positive results of the phase 3 ZUMA-7 and TRANSFORM clinical trials. This review addresses the role of CAR-T therapy and autologous stem cell transplantation in the treatment of these patients and other approved optio

SUBMITTER: Garcia-Sancho AM 

PROVIDER: S-EPMC10779497 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature